Jan 14, 2021

Featuring a roundtable discussion with Drs Adil Daud, Michael Postow, Hussein Tawbi and Jeffrey S Weber on the following topics:

• Metastatic Disease
  • Introduction
  • Case: A woman in her early 50s with Stage IV melanoma and a solitary brain metastasis
  • Case: A man in his early 20s with metastatic melanoma with a BRAF mutation and CNS metastases
  • Case: A woman in her mid-80s with metastatic melanoma with a BRAF mutation who received encorafenib/binimetinib
  • Case: A man in his early 60s with widespread metastatic melanoma
  • Case: A man in his mid-80s with metastatic melanoma with a BRAF mutation and a PD-L1 CPS (combined positive score) of 10%
  • Available evidence and ongoing research with the combination of BRAF/MEK inhibitors and immunotherapy for advanced melanoma with a BRAF mutation
  • Assessment of PD-L1 level in deciding on first-line therapy for patients with metastatic melanoma
  • First-line therapy options for younger patients with metastatic melanoma with BRAF mutations
  • Case: A woman in her early 50s with melanoma with a BRAF mutation and brain metastases
  • Case: A man in his mid-70s with metastatic melanoma with a BRAF mutation
  • Similarities and differences among BRAF/MEK inhibitor combinations (dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib) used in the treatment of metastatic melanoma with a BRAF mutation
  • Effects of the COVID-19 pandemic on the clinical care of patients with melanoma
  • Case: A man in his mid-20s with newly diagnosed metastatic melanoma with a BRAF V600E mutation
  • Case: A woman in her late 40s with metastatic melanoma with a BRAF mutation
  • Thresholds for dose reduction and delay with dabrafenib/trametinib, vemurafenib/cobimetinib and encorafenib/binimetinib
• Adjuvant Systemic Therapy
  • Case: A man in his early 70s with Stage IIIC melanoma and diabetes
  • Case: A woman in her early 50s with melanoma with a high tumor mutation burden
  • Case: A woman in her mid-60s with Stage IIIC melanoma with a BRAF V600E mutation
  • Use of encorafenib/binimetinib or vemurafenib/cobimetinib as adjuvant therapy
  • Potential contraindications for immune checkpoint inhibitors (eg, prior autoimmune disease, transplant)
  • Case: A woman in her early 50s with localized melanoma and a BRAF V600E mutation
  • Case: A woman in her early 70s with localized melanoma and a BRAF V600E mutation; duration of adjuvant therapy with BRAF/MEK combinations
  • Case: An otherwise healthy man in his early 30s with localized melanoma and a BRAF V600K mutation

CME information and select publications